# BIO RAD

# BIOPLEX 2200 HSV-1 AND HSV-2 IgG 510(k) SUMMARY

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92. . . ;:

<table><tr><td>510(k) Number</td><td>510(k) Summary Report Date</td></tr><tr><td>k090409</td><td>May 1. 2009</td></tr></table>

# MANUFACTURER INFORMATION

<table><tr><td rowspan=1 colspan=2>Manufacturer</td></tr><tr><td rowspan=1 colspan=1>Manufacturer Address</td><td rowspan=1 colspan=1>Bio-Rad Laboratories, Inc. .. .Clinical Systems Division4000 Alfred Nobel DriveHercules, CA 94547</td></tr><tr><td rowspan=1 colspan=1>Telephone</td><td rowspan=1 colspan=1>(510) 724-7000</td></tr><tr><td rowspan=1 colspan=1>Establishment Registration No.</td><td rowspan=1 colspan=1>2915274</td></tr><tr><td rowspan=1 colspan=1>Owner / Operator</td><td rowspan=1 colspan=1>Bio-Rad Laboratories, Inc.4000 Alfred Nobel DriveHercules, CA 94547</td></tr><tr><td rowspan=1 colspan=1>Owner / Operator No.</td><td rowspan=1 colspan=1>9929003                             ;</td></tr><tr><td rowspan=1 colspan=1>Official Correspond</td><td rowspan=1 colspan=1>Official Correspondent for the BioPlex 2200 HSV-1 and HSV-2 IgG</td></tr><tr><td rowspan=1 colspan=1>Official Correspondent Address</td><td rowspan=1 colspan=1>Bio-Rad Laboratories6565 185t Ave NERedmond, WA 98052</td></tr><tr><td rowspan=1 colspan=1>Telephone</td><td rowspan=1 colspan=1>425-881-8300</td></tr><tr><td rowspan=1 colspan=1>Establishment Registration No.</td><td rowspan=1 colspan=1>3022521</td></tr><tr><td rowspan=1 colspan=1>Owner / Operator</td><td rowspan=1 colspan=1>Bio-Rad Laboratories6565 185th Ave NERedmond, WA 98052</td></tr><tr><td rowspan=1 colspan=1>Official Correspondent</td><td rowspan=1 colspan=1>Mr. Christopher Bentsen</td></tr><tr><td rowspan=1 colspan=1>Telephone</td><td rowspan=1 colspan=1>(425) 498-1709</td></tr><tr><td rowspan=1 colspan=1>Fax</td><td rowspan=1 colspan=1>(425) 498-1651</td></tr></table>

# CLASSIFICATION INFORMATION

<table><tr><td colspan="1" rowspan="1">Classification Name</td><td colspan="1" rowspan="1">Enzyme Linked Immunosorbent Assay, Herpes SimplexVirus, HSV-1</td></tr><tr><td colspan="1" rowspan="1">Common Name...</td><td colspan="1" rowspan="1">Multi-Analyte Detection System HSV-1 and HSV-2 IgG</td></tr><tr><td colspan="1" rowspan="1">Product Trade Name</td><td colspan="1" rowspan="1">BioPlex 2200 HSV-1 and HSV-2 IgG on the BioPlex 2200Multi-Analyte Detection System</td></tr><tr><td colspan="1" rowspan="1">Device Class</td><td colspan="1" rowspan="1">Class iI</td></tr><tr><td colspan="1" rowspan="1">Classification Panel</td><td colspan="1" rowspan="1">Microbiology</td></tr><tr><td colspan="1" rowspan="1">Regulation Number</td><td colspan="1" rowspan="1">866.3305</td></tr><tr><td colspan="1" rowspan="1">Product Code</td><td colspan="1" rowspan="1">MXJ</td></tr><tr><td colspan="1" rowspan="1">Classification Name</td><td colspan="1" rowspan="1">Enzyme Linked Immunosorbent Assay, Herpes SimplexVirus, HSV-2</td></tr><tr><td colspan="1" rowspan="1">Common Name:</td><td colspan="1" rowspan="1">Multi-Analyte Detection System HSV-1 and HSV-2 IgG</td></tr><tr><td colspan="1" rowspan="1">Product Trade Name</td><td colspan="1" rowspan="1">BioPlex 2200 HSV-1 and HSV-2 IgG on the BioPlex 2200Multi-Analyte Detection System</td></tr><tr><td colspan="1" rowspan="1">Device Class</td><td colspan="1" rowspan="1">Class II</td></tr><tr><td colspan="1" rowspan="1">Classification Panel</td><td colspan="1" rowspan="1">Microbiology</td></tr><tr><td colspan="1" rowspan="1">Regulation Number</td><td colspan="1" rowspan="1">866.3305</td></tr><tr><td colspan="1" rowspan="1">Product Code</td><td colspan="1" rowspan="1">MYF</td></tr></table>

# LEGALLY MARKETED EQUIVALENT (SE) DEVICES

<table><tr><td rowspan=1 colspan=1>Comparative FDA ClearedPREDICATE DEVICE</td><td rowspan=1 colspan=1>510(k) Number</td><td rowspan=1 colspan=1>DecisionDate</td></tr><tr><td rowspan=1 colspan=1>Focus HerpesSelect 1 ELISA IgG</td><td rowspan=1 colspan=1>k021429</td><td rowspan=1 colspan=1>7/29/2002</td></tr><tr><td rowspan=1 colspan=1>Focus HerpesSelect 2 ELISA IgG</td><td rowspan=1 colspan=1>k021486</td><td rowspan=1 colspan=1>8/1/2002</td></tr><tr><td rowspan=1 colspan=1>Focus HerpesSelect 1 and 2 Immunoblot IgG</td><td rowspan=1 colspan=1>k000238</td><td rowspan=1 colspan=1>4/14/2000</td></tr></table>

- ' - · — - ¸

# DEVICE DESCRIPTION

The BioPlex 2200 HSV-1 & HSV-2 IgG kit uses multiplex flow immunoassay, a methodology that greatly resembles traditional ElA, but permits simultaneous detection and identification of many antibodies in a single tube.

Two different populations of dyed beads are each coated with antigens associated with herpes simplex virus, types 1 and 2. The BioPlex 2200 System combines an aliquot of patient sample, sample diluent, and bead set reagent into a reaction vessel. The mixture is incubated at $\mathfrak { s } 7 ^ { \circ } \mathfrak { C }$ After a wash cycle, anti-human $| \mathfrak { g } \mathfrak { G }$ antibody, conjugated to phycoerythrin (PE), is added to the dyed beads and this mixture is incubated at $3 7 ^ { \circ } \circ$ , The excess conjugate is removed in another wash cycle, and the beads are re-suspended in wash buffer. The bead mixture then passes through the detector. The identity of the dyed beads is determined by the fluorescence of the dyes, and the amount of antibody captured by the antigen is determined by the fluorescence of the attached PE. Raw data is calculated in relative fluorescence intensity (RFI).

Three additional dyed beads, an Internal Standard Bead (ISB), a Serum Verification Bead (SVB) and a Reagent Blank Bead (RBB) are present in each reaction mixture to verify detector response, the addition of serum to the reaction vessel and the absence of significant non-specific binding in serum. Refer to the BioPlex 2200 Syster Operation Manual for more information.

The instrument is calibrated using a set of 4 distinct calibrator vials, supplied separately by BioRad Laboratories.

# BIO RAD

# KIT COMPONENTS

BioPlex 2200 HSV-1 & HSV-2 IgG Reagent Pack ( 665-3350). The reagent pack contains supplies sufficient for 100 tests.

<table><tr><td rowspan=1 colspan=1>Vial</td><td rowspan=1 colspan=1>Description</td></tr><tr><td rowspan=1 colspan=1>Bead Set</td><td rowspan=1 colspan=1>One (1) 10 mL vial, containing dyed beads coated with HSV-1 and HSV-2IgG antigens, an Internal Standard bead (ISB), a Serum Verification bead(SVB), and a Reagent Blank bead (RBB) in buffer with Glycerol and proteinstabilizers (bovine). ProClin 300 (0.3%), sodium benzoate (0.1%) andsodium azide (&lt;0.1%) as preservatives.</td></tr><tr><td rowspan=1 colspan=1>Conjugate</td><td rowspan=1 colspan=1>One (1) 5 mL vial, containing phycoerythrin conjugated murine monoclonalanti-human IgG antibody and phycoerythrin conjugated murine monoclonalanti-human FXIill antibody*, in buffer with protein stabilizers (bovine).ProClin~ 300 (0.3%), sodium benzoate (0.1%) and sodium azide (&lt;0.1%)as preservatives.Tgn Xin rhe c  in the reaction vessel.</td></tr><tr><td rowspan=1 colspan=1>Sample Diluent</td><td rowspan=1 colspan=1>One (1) 10 mL vial, containing buffer with protein stabilizers (bovine andmurine). ProClin™ 300 (0.3%), sodium benzoate (0.1%) and sodium azide(&lt;0.1%) as preservatives.</td></tr></table>

ADDITIONAL REQUIRED ITEMS, AVAILABLE FROM BIO-RAD   

<table><tr><td rowspan=1 colspan=1>Catalog #</td><td rowspan=1 colspan=1>Description</td></tr><tr><td rowspan=1 colspan=1>663-3300</td><td rowspan=1 colspan=1>BioPlex 2200 HSV-1 &amp; HSV-2 IgG Calibrator Set: Four (4) 0.5 mL vials,each containing human antibodies to HSV-1 and HSV-2 IgG derived fromhuman disease state plasma, in a human serum matrix made fromdefibrinated plasma. All calibrators contain ProClin ™ 300 (0.3%), sodiumbenzoate (0.1%) and sodium azide (&lt;0.1%) as preservatives.</td></tr><tr><td rowspan=1 colspan=1>663-3330</td><td rowspan=1 colspan=1>BioPlex 2200 HSV-1 &amp; HSV-2 IgG Control Set: Two (2) 1.5 mL PositiveControl serum vials, each containing human antibodies to HSV-1 and HSV-2 IgG derived from human disease state plasma, in a human serum matriximade from defibrinated plasma;&quot;and two (2)1:5 mL Negative Control serumvials, in a human serum matrix made from defibrinated plasma. All controlscontain ProClin ™m 300 (0.3%), sodium benzoate (0.1%) and sodium azide(&lt;0.1%) as preservatives.</td></tr><tr><td rowspan=1 colspan=1>660-0817</td><td rowspan=1 colspan=1>BioPlex 2200 System Sheath Fluid: Two (2) 4 L bottles containingPhosphate Buffered Saline (PBS). ProClin® 300 (0.3%) and Sodium azide(0.1%) as preservatives.</td></tr><tr><td rowspan=1 colspan=1>660-0818</td><td rowspan=1 colspan=1>BioPlex 2200 System Wash Solution: One (1) 10 L bottle containingPhosphate Buffered Saline (PBS) and Tween 20. ProClin® 300 (0.3%) andSodium azide (0.1%) as preservatives.</td></tr><tr><td rowspan=1 colspan=1>660-0000</td><td rowspan=1 colspan=1>BioPlex 2200 Instrument and Software.  .&#x27;,</td></tr></table>

# INTENDED USE / INDICATIONS FOR USE

The BioPlex™ 2200 HSV-1 & HSV-2 IgG kit is a multiplex flow immunoassay intended for the qualitative detection and differentiation of IgG antibodies to herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2) in human serum and EDTA or heparinized plasma. The test is indicated for sexually active individuals and expectant mothers as an aid for the presumptive diagnosis of HSV-1 or HSV-2 infection. The predictive value of positive or negative results depends on the population's prevalence and the pretest likelihood of HSV-1 and HSV-2.

The test is not FDA cleared for screening blood or plasma donors. The performance of this assay has not been established for use in a pediatric population, neonates and immunocompromised patients or for use at point of care facilities.

The BioPlex 2200 HSV-1 & HSV-2 IgG kit is intended for use with the Bio-Rad BioPlex 2200 System.

# TECHNOLOGICAL CHARACTERISTICS

The following tables summarize similarities and differences between the BioPlex 2200 HSV-1 and HSV-2 IgG Kit and the predicate device used in comparative studies with the BioPlex 2200 HSV1 and HSV-2 IgG Kit.

BioPlex 2200 HSV-1 and HSV-2 IgG Assay vs. Predicate HSV 1 and 2 Immunoblot IgG

Table 1: Similarities between reagents and materials   

<table><tr><td rowspan=1 colspan=1>Similarities betweenComponents /Materials</td><td rowspan=1 colspan=1>BioPlex 2200 HSV-1 and HSV-2IgG Kit</td><td rowspan=1 colspan=1>Predicate HSV 1 and 2Immunoblot IgG</td></tr><tr><td rowspan=1 colspan=1>Reagents</td><td rowspan=1 colspan=1>Wash Solution, Sample Diluent.</td><td rowspan=1 colspan=1>Wash Buffer, Diluent.</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>Negative Control and multi-   &lt;il.:analyte Positive Control. Tr.{^</td><td rowspan=1 colspan=1>Negative Control andrPositive/Cutoff:Control.</td></tr></table>

Table 2: Similarities between reagents with regard to function and use   

<table><tr><td rowspan=1 colspan=1>Similarities betweenFunction and Use</td><td rowspan=1 colspan=1>BioPlex 2200 HSV-1 and HSV-2IgG Kit</td><td rowspan=1 colspan=1>Focus HerpesSelect 1 and 2Immunoblot IgG</td></tr><tr><td rowspan=1 colspan=1>Analyte Detection</td><td rowspan=1 colspan=1>Qualitative detection of IgGantibodies to HSV-1 and HSV-2.</td><td rowspan=1 colspan=1>Qualitative detection of IgGantibodies to HSV-1 and HSV-2.</td></tr></table>

Table 3: Differences between reagents and materials   

<table><tr><td rowspan=1 colspan=1>Differences between.Components /Materials</td><td rowspan=1 colspan=1>BioPlex 2200-HSV-1 and HSV-2-IgG Kit</td><td rowspan=1 colspan=1>Focus HerpesSelect 1 and 2Immunoblot IgG</td></tr><tr><td rowspan=1 colspan=1>Solid Phase</td><td rowspan=1 colspan=1>Bead reagent - dyed antigencoated beads.</td><td rowspan=1 colspan=1>Treated nitrocellulose membranestrips containing antigen bands.</td></tr><tr><td rowspan=1 colspan=1>Reagents</td><td rowspan=1 colspan=1>Conjugate: Anti-human IgG /Phycoerythrin.</td><td rowspan=1 colspan=1>Conjugate: goat anti-human IgG/ alkaline phosphatase, BlottingPowder, Substrate.</td></tr><tr><td rowspan=1 colspan=1>Sheath Fluid</td><td rowspan=1 colspan=1>Sheath Fluid is used to suspendthe bead reagent and introduce itinto the detector.</td><td rowspan=1 colspan=1>Not similar; not utilized in blotassays..  </td></tr><tr><td rowspan=1 colspan=1>Calibrator(s)</td><td rowspan=1 colspan=1>Calibrators.</td><td rowspan=1 colspan=1>None.</td></tr></table>

# BioPlex 2200 HSV-1 and HSV-2 IgG 510(k) Summary (5-1-09)

Table 4: Differences between reagents with regard to function and use   

<table><tr><td rowspan=1 colspan=1>Differences betweenFunction and Use</td><td rowspan=1 colspan=1>BioPlex 2200 HSV-1 and HSV-2IgG Kit</td><td rowspan=1 colspan=1>Focus HerpesSelect 1 and 2Immunoblot IgG</td></tr><tr><td rowspan=1 colspan=1>Technique</td><td rowspan=1 colspan=1>Flow immunoassay.</td><td rowspan=1 colspan=1>Immunoblot.</td></tr><tr><td rowspan=1 colspan=1>Matrices</td><td rowspan=1 colspan=1>Serum and plasma.</td><td rowspan=1 colspan=1>Serum.</td></tr></table>

……

# PERFORMANCE SUMMARY

# A. Expected Values

# Prevalence

The observed prevalence and expected values for the BioPlex 2200 HSV-1 & HSV-2 IgG kit are presented by age and gender for serum samples from sexually active individuals where an HSV-1 test was ordered $( N = 2 8 9 )$ ; sexually active individuals where an Hsv-2 test was ordered $( N = 2 8 6 )$ and for expectant mothers $( N = 3 9 9 )$ ). Results are shown in Tables 5 - 11,

Table 5: Sexually Active Individuals With an HSV-1 Test Ordered: BioPlex 2200 HSV-1 IgG $( N = 2 8 9 )$ EP   

<table><tr><td rowspan=3 colspan=1>Age in Years</td><td rowspan=3 colspan=1>Gendei</td><td rowspan=1 colspan=6>BioPlex 2200 HSV-1 IgG</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=2>Positive</td><td rowspan=1 colspan=2>Equlvocal</td><td rowspan=1 colspan=2>Nepative</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>96</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>96</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>N</td></tr><tr><td rowspan=2 colspan=1>18-20</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>85.7%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>14.3%</td><td rowspan=1 colspan=1>7</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>66.7%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>33.390</td><td rowspan=1 colspan=1>12</td></tr><tr><td rowspan=2 colspan=1>21-30</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>62.5%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>9  4</td><td rowspan=1 colspan=1>37.5%</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>58.3%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>-0.094</td><td rowspan=1 colspan=1>1m.15.</td><td rowspan=1 colspan=1>t: 41.7%</td><td rowspan=1 colspan=1>36</td></tr><tr><td rowspan=2 colspan=1>31-40</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>86.4%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>4.5%</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>9.1%</td><td rowspan=1 colspan=1>22</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>71.9%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3.1%</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>25.0%</td><td rowspan=1 colspan=1>32</td></tr><tr><td rowspan=2 colspan=1>41-50</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>81.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>19.0%</td><td rowspan=1 colspan=1>21</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>74.59%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>23.5%</td><td rowspan=1 colspan=1>51</td></tr><tr><td rowspan=2 colspan=1>51-60</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>64.5%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>38.5%</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>74.2%</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>6.5%</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>19.4%6</td><td rowspan=1 colspan=1>31</td></tr><tr><td rowspan=2 colspan=1>61-70</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>68.8%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>31.3%0</td><td rowspan=1 colspan=1>16</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>75.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>25.0%</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=2 colspan=1>71-80</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>50.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>50.0V0.</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>IM</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=2 colspan=1>81-89</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0:</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>207</td><td rowspan=1 colspan=1>71.6%</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>1.79</td><td rowspan=1 colspan=1>I7</td><td rowspan=1 colspan=1>26.0%</td><td rowspan=1 colspan=1>289</td></tr></table>

Note: Due to rounding numbers across columns may not total $100 \%$ .

BiPx 2200HSV-andHSV- G0k 1) $\lim \limits _ { i  \infty } \cdots \lim \limits _ { n  \infty } \frac { i } { 1 + \cdots + \frac { 1 } { 2 } } \pi ( s - \cdots )$ . Page 5 of 17

# BIO RAD

Table 6:Sexually Active Individuals With an HSV-2 Test Ordered: BioPlex 2200 HSV-2 IgG $( N = 2 8 \theta )$   

<table><tr><td rowspan=3 colspan=1>Age in Years</td><td rowspan=3 colspan=1>Gender</td><td rowspan=1 colspan=6>BioPlex 220D HSV-2 IgG</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=2>Positive</td><td rowspan=1 colspan=2>Equivocal</td><td rowspan=1 colspan=2>Negative</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>N</td></tr><tr><td rowspan=2 colspan=1>18-20</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>50.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>50.0%</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>22.2%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>77.8%</td><td rowspan=1 colspan=1>9</td></tr><tr><td rowspan=2 colspan=1>21-30</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>38.5%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>61.5%</td><td rowspan=1 colspan=1>26</td></tr><tr><td rowspan=1 colspan=1>M$</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>36.6%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>63.4%</td><td rowspan=1 colspan=1>41</td></tr><tr><td rowspan=2 colspan=1>31-40</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>199.2%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>30.8%</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>32.0%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>66.0%</td><td rowspan=1 colspan=1>50</td></tr><tr><td rowspan=2 colspan=1>41-50</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>52.9Mb</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>47.196</td><td rowspan=1 colspan=1>17</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>40.496</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>59.6%</td><td rowspan=1 colspan=1>52</td></tr><tr><td rowspan=2 colspan=1>51-60</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>46.7%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>53.3%</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>37.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>63.07%</td><td rowspan=1 colspan=1>27</td></tr><tr><td rowspan=2 colspan=1>61-70</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>50.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>50.0%</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>1v1</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>20.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>80.0%</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=2 colspan=1>&#x27;71-80</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>· •0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=2 colspan=1>81-89</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>109</td><td rowspan=1 colspan=1>38.1%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.4%</td><td rowspan=1 colspan=1>176</td><td rowspan=1 colspan=1>61.5%</td><td rowspan=1 colspan=1>286</td></tr></table>

Table 7: Sexually Active Individuals With an HSV-1 Test Ordered: BioPlex 2200 HSV-1 IgG and HSV-2 IgG Dual Positive $( N = 2 8 9 )$ EMP   

<table><tr><td rowspan=3 colspan=1>Age in Years</td><td rowspan=3 colspan=1>Genler</td><td rowspan=2 colspan=2>BioPlex 2200, HSV-1 &amp; HSV-2 IgGDual Positive</td><td rowspan=2 colspan=1>-:Total</td><td></td></tr><tr><td rowspan=19 colspan=1>. -. ——</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>N</td></tr><tr><td rowspan=2 colspan=1>18-20</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>42.9%</td><td rowspan=1 colspan=1>7</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>25.0%</td><td rowspan=1 colspan=1>12</td></tr><tr><td rowspan=2 colspan=1>21-30</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>41.7%</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>27.8%</td><td rowspan=1 colspan=1>36</td></tr><tr><td rowspan=2 colspan=1>31-40</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>63.6%</td><td rowspan=1 colspan=1>22</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>.  12   -</td><td rowspan=1 colspan=1>37.5%.</td><td rowspan=1 colspan=1>32</td></tr><tr><td rowspan=2 colspan=1>41-50</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>47.6%</td><td rowspan=1 colspan=1>21</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>17.6%</td><td rowspan=1 colspan=1>51</td></tr><tr><td rowspan=2 colspan=1>51-60</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>23.1%</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>25.8%</td><td rowspan=1 colspan=1>31</td></tr><tr><td rowspan=2 colspan=1>61-70</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>18.8%</td><td rowspan=1 colspan=1>16</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>25.0%</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=2 colspan=1>71-80</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>50.0%</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>-0-</td><td rowspan=1 colspan=1>-0.0%</td><td rowspan=1 colspan=1>2-</td></tr><tr><td rowspan=2 colspan=1>81-89</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>91</td><td rowspan=1 colspan=1>31.5%</td><td rowspan=1 colspan=1>289</td></tr></table>

# BioPlex 2200 HSV-1 and HSV-2 IgG 510(k) Summary (5-1-09)

Table 8. Sexually Active Individuals With an HSV-2 Test Ordered: BioPlex 2200 HSV-1 IgG and HSV-2 IgG Dual Positive $( N = 2 8 0 )$   

<table><tr><td rowspan=2 colspan=1>Age in Years</td><td rowspan=2 colspan=1>Gender</td><td rowspan=1 colspan=2>BioPlex 2200 HSV-1 &amp; HSV-2 IgGDual Positive</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>N</td></tr><tr><td rowspan=2 colspan=1>18-20</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>25.0%</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>.1</td><td rowspan=1 colspan=1>·1  11.1%1&quot;</td><td rowspan=1 colspan=1>&quot;,; 94. -&quot;</td></tr><tr><td rowspan=2 colspan=1>21-30</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>26.9%</td><td rowspan=1 colspan=1>26</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>22.0%</td><td rowspan=1 colspan=1>41</td></tr><tr><td rowspan=2 colspan=1>31-40</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>30.8%</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>20.0%</td><td rowspan=1 colspan=1>50</td></tr><tr><td rowspan=2 colspan=1>41-50</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>35.3%</td><td rowspan=1 colspan=1>17</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>25.0%</td><td rowspan=1 colspan=1>52</td></tr><tr><td rowspan=2 colspan=1>51-60</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>26.7%</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>25.9%</td><td rowspan=1 colspan=1>27</td></tr><tr><td rowspan=2 colspan=1>61-70-</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>50.0%</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>20.0%</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=2 colspan=1>71-80</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=2 colspan=1>81-89</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>1 (</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>.24.5%</td><td rowspan=1 colspan=1>286</td></tr></table>

Table 9: Expectant Mothers: BioPlex 2200 HSV-1 IgG (N = 399)   

<table><tr><td rowspan=3 colspan=1>Age in Years·. ·</td><td rowspan=1 colspan=6>BioPlex 2200 HSV-1 IgG</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=2>Positive</td><td rowspan=1 colspan=2>Equdivocal</td><td rowspan=1 colspan=2>Negative</td></tr><tr><td rowspan=1 colspan=1>- N</td><td rowspan=1 colspan=1>4 </td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>21%-</td><td rowspan=1 colspan=1>a …N</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>N</td></tr><tr><td rowspan=1 colspan=1>14-20</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>58.3%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>41.7%</td><td rowspan=1 colspan=1>60</td></tr><tr><td rowspan=1 colspan=1>21-30</td><td rowspan=1 colspan=1>133</td><td rowspan=1 colspan=1>70.7%</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1>28.246</td><td rowspan=1 colspan=1>188</td></tr><tr><td rowspan=1 colspan=1>31-40</td><td rowspan=1 colspan=1>98</td><td rowspan=1 colspan=1>76.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>24.0%</td><td rowspan=1 colspan=1>129</td></tr><tr><td rowspan=1 colspan=1>41-50</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%0</td><td rowspan=1 colspan=1>21</td></tr><tr><td rowspan=1 colspan=1>Unknown</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>288</td><td rowspan=1 colspan=1>72.2%</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0.5%</td><td rowspan=1 colspan=1>109</td><td rowspan=1 colspan=1>27.3%</td><td rowspan=1 colspan=1>399</td></tr></table>

![](images/2e4c4019d970046562f0eb7b5775edf6c2796b3bdd60d5fa5861974f330caf57.jpg)

Table 10: Expectant Mothers: BioPlex 2200 HSV-2 IgG (N = 399)   

<table><tr><td rowspan=3 colspan=1>Auge in Years</td><td rowspan=1 colspan=6>BioPlex 2200 HS4-2 lgG</td><td rowspan=2 colspan=1>otal</td></tr><tr><td rowspan=1 colspan=2>Positive</td><td rowspan=1 colspan=2>Equrivocal</td><td rowspan=1 colspan=2>Negative</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>96</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>96</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>N</td></tr><tr><td rowspan=1 colspan=1>14-20</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>20.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>80.0%</td><td rowspan=1 colspan=1>60</td></tr><tr><td rowspan=1 colspan=1>21-30</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>35.1%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>122</td><td rowspan=1 colspan=1>64.9%</td><td rowspan=1 colspan=1>188</td></tr><tr><td rowspan=1 colspan=1>31-40</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>52.7%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>61</td><td rowspan=1 colspan=1>47.3%</td><td rowspan=1 colspan=1>129</td></tr><tr><td rowspan=1 colspan=1>41-50</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>52.4%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>47.6%</td><td rowspan=1 colspan=1>21</td></tr><tr><td rowspan=1 colspan=1>Unknown</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>157</td><td rowspan=1 colspan=1>39.3%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>242</td><td rowspan=1 colspan=1>60.7%</td><td rowspan=1 colspan=1>309</td></tr></table>

Table 11: Expectant Mothers: BioPlex 2200 HSV-1 IgG & HSV-2 IgG Dual Positive $( N = 3 9 9 )$   

<table><tr><td rowspan=2 colspan=1>Age In Years</td><td rowspan=1 colspan=2>BioPlex 220D HSV-1 &amp; HSV-2 IgGDual Positive</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>4%</td><td rowspan=1 colspan=1>N</td></tr><tr><td rowspan=1 colspan=1>14-20</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>15.0%</td><td rowspan=1 colspan=1>60</td></tr><tr><td rowspan=1 colspan=1>21-30</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>24.5%</td><td rowspan=1 colspan=1>168</td></tr><tr><td rowspan=1 colspan=1>31-40</td><td rowspan=1 colspan=1>56</td><td rowspan=1 colspan=1>43.4%</td><td rowspan=1 colspan=1>129</td></tr><tr><td rowspan=1 colspan=1>41-50</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>52.4%</td><td rowspan=1 colspan=1>21</td></tr><tr><td rowspan=1 colspan=1>Unknown</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>122</td><td rowspan=1 colspan=1>30.6%</td><td rowspan=1 colspan=1>399</td></tr></table>

Prevalence of HSv-1 or HSV-2 infection may vary by geographical area, age, or gender. The predictive value of the assay is dependent on the prevalence of HSV infection. Tables 12 - 14 present the observed prevalence and predictive values as well as hypothetical predictive values for decreasing prevalence rates. The hypothetical HSV-1 predictive values presented are based on BioPlex 2200 HSV-1 IgG $9 7 . 6 \%$ sensitivity and $9 0 . 1 \%$ specificity in sexually active individuals with an HSV-1 test ordered and $9 6 . 3 \%$ sensitivity and $9 9 . 0 \%$ specificity in expectant mothers. The hypothetical HSV-2 predictive values presented are based on BioPlex 2200 HSV-2 IgG sensitivity of $9 0 . 6 \%$ and specificity $9 8 . 2 \%$ in sexually active adults with an HSv-2 test ordered and a $9 6 . 9 \%$ sensitivity and $100 \%$ specificity in expectant mothers.

Table 12: Summary of. Observed Prevalence, Rositive Predictive Value (PPV), Negative Predictive Value (NPV)   

<table><tr><td rowspan=2 colspan=1>Population</td><td rowspan=2 colspan=1>N</td><td rowspan=1 colspan=3>BioPlex 2200 HSV-1 IgG</td><td rowspan=1 colspan=3>BioPlex 2200 HSV-2 IgG</td></tr><tr><td rowspan=1 colspan=1>Peaee</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>MA</td><td rowspan=1 colspan=1>peeee</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Sexually Active Individuals withan HSy-1 Test ordered</td><td rowspan=1 colspan=1>289</td><td rowspan=1 colspan=1>71.6%</td><td rowspan=1 colspan=1>96.2%</td><td rowspan=1 colspan=1>93.6%</td><td rowspan=1 colspan=1>HVA</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Sexually Active Individuals withan HSv-2 Test ordered-</td><td rowspan=1 colspan=1>286</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>NA.</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>3.1%</td><td rowspan=1 colspan=1>97.3%</td><td rowspan=1 colspan=1>93.8%</td></tr><tr><td rowspan=1 colspan=1>Expectant Mothers</td><td rowspan=1 colspan=1>399</td><td rowspan=1 colspan=1>72.2%</td><td rowspan=1 colspan=1>99.7%</td><td rowspan=1 colspan=1>90.1%</td><td rowspan=1 colspan=1>39.3%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>97.9%</td></tr></table>

# BIO RAD

Table 13: HSV-1 Hypothetical Predictive Values by Prevalence   

<table><tr><td rowspan=2 colspan=1>Prevalence</td><td rowspan=1 colspan=2>Sexually Active Individuabs</td><td rowspan=1 colspan=2>Expectant Mothers</td></tr><tr><td rowspan=1 colspan=1>PPV</td><td rowspan=1 colspan=1>NPV</td><td rowspan=1 colspan=1>PPV</td><td rowspan=1 colspan=1>NPV</td></tr><tr><td rowspan=1 colspan=1>80%</td><td rowspan=1 colspan=1>97.5%</td><td rowspan=1 colspan=1>90.4%</td><td rowspan=1 colspan=1>99.7%</td><td rowspan=1 colspan=1>87.0%</td></tr><tr><td rowspan=1 colspan=1>70%</td><td rowspan=1 colspan=1>95.8%</td><td rowspan=1 colspan=1>94.1%</td><td rowspan=1 colspan=1>99.6%</td><td rowspan=1 colspan=1>92.0%</td></tr><tr><td rowspan=1 colspan=1>604%</td><td rowspan=1 colspan=1>93.7%</td><td rowspan=1 colspan=1>06.2%</td><td rowspan=1 colspan=1>99.3%</td><td rowspan=1 colspan=1>94.7%</td></tr><tr><td rowspan=1 colspan=1>504</td><td rowspan=1 colspan=1>90.8%</td><td rowspan=1 colspan=1>97.4%</td><td rowspan=1 colspan=1>99.0%</td><td rowspan=1 colspan=1>96.4%</td></tr><tr><td rowspan=1 colspan=1>.409</td><td rowspan=1 colspan=1>86.89</td><td rowspan=1 colspan=1>98.3%</td><td rowspan=1 colspan=1>98.5%</td><td rowspan=1 colspan=1>97.6%</td></tr><tr><td rowspan=1 colspan=1>30%</td><td rowspan=1 colspan=1>80.9%</td><td rowspan=1 colspan=1>98.9%</td><td rowspan=1 colspan=1>97.6%</td><td rowspan=1 colspan=1>98.4%</td></tr><tr><td rowspan=1 colspan=1>25%</td><td rowspan=1 colspan=1>78.7%</td><td rowspan=1 colspan=1>99.1%</td><td rowspan=1 colspan=1>97.0%</td><td rowspan=1 colspan=1>98.8%</td></tr><tr><td rowspan=1 colspan=1>20%</td><td rowspan=1 colspan=1>71.1%</td><td rowspan=1 colspan=1>99.3%</td><td rowspan=1 colspan=1>96.0%</td><td rowspan=1 colspan=1>99.1%</td></tr><tr><td rowspan=1 colspan=1>15%</td><td rowspan=1 colspan=1>63.5%</td><td rowspan=1 colspan=1>99.5%</td><td rowspan=1 colspan=1>94.4%</td><td rowspan=1 colspan=1>99,39</td></tr><tr><td rowspan=1 colspan=1>10%</td><td rowspan=1 colspan=1>52.3%</td><td rowspan=1 colspan=1>99.7%</td><td rowspan=1 colspan=1>91.5%</td><td rowspan=1 colspan=1>99.6%</td></tr><tr><td rowspan=1 colspan=1>5%</td><td rowspan=1 colspan=1>34.2%</td><td rowspan=1 colspan=1>99.9%</td><td rowspan=1 colspan=1>83.5%</td><td rowspan=1 colspan=1>99.8%</td></tr></table>

Table 14: HSV-2 Hypothetical Predictive Values by Prevalence   

<table><tr><td rowspan=2 colspan=1>Prevalence</td><td rowspan=1 colspan=2>Sexually Ac tive Individuaks</td><td rowspan=1 colspan=2>Expectant Mothers</td></tr><tr><td rowspan=1 colspan=1>PPV</td><td rowspan=1 colspan=1>NPV</td><td rowspan=1 colspan=1>PPV</td><td rowspan=1 colspan=1>NPY</td></tr><tr><td rowspan=1 colspan=1>80%</td><td rowspan=1 colspan=1>99.5%</td><td rowspan=1 colspan=1>72.3%</td><td rowspan=1 colspan=1>1C0%</td><td rowspan=1 colspan=1>89.0%</td></tr><tr><td rowspan=1 colspan=1>7090</td><td rowspan=1 colspan=1>99.2%</td><td rowspan=1 colspan=1>81.79</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>93.3%</td></tr><tr><td rowspan=1 colspan=1>60%</td><td rowspan=1 colspan=1>98.7%</td><td rowspan=1 colspan=1>87.496</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>95.6%</td></tr><tr><td rowspan=1 colspan=1>50%</td><td rowspan=1 colspan=1>98.1%</td><td rowspan=1 colspan=1>91.3%</td><td rowspan=1 colspan=1>100%•</td><td rowspan=1 colspan=1>97.0%</td></tr><tr><td rowspan=1 colspan=1>40%</td><td rowspan=1 colspan=1>97.196</td><td rowspan=1 colspan=1>04.0%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>98.0%</td></tr><tr><td rowspan=1 colspan=1>30%·</td><td rowspan=1 colspan=1>95.6%</td><td rowspan=1 colspan=1>08.1%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>98.7%</td></tr><tr><td rowspan=1 colspan=1>25%</td><td rowspan=1 colspan=1>94.4%</td><td rowspan=1 colspan=1>96.9%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>99.0%</td></tr><tr><td rowspan=1 colspan=1>20%</td><td rowspan=1 colspan=1>92.6%</td><td rowspan=1 colspan=1>97.7%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>99.2%</td></tr><tr><td rowspan=1 colspan=1>15%</td><td rowspan=1 colspan=1>89.9%</td><td rowspan=1 colspan=1>98.3%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>99.5%</td></tr><tr><td rowspan=1 colspan=1>10%</td><td rowspan=1 colspan=1>84.8%</td><td rowspan=1 colspan=1>98.0%</td><td rowspan=1 colspan=1>1004%</td><td rowspan=1 colspan=1>99.7%</td></tr><tr><td rowspan=1 colspan=1>5%</td><td rowspan=1 colspan=1>72.6%</td><td rowspan=1 colspan=1>99.5%</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>99.8%</td></tr></table>

1

# B. Comparative Testing

Table 15 summarizes the performance of the BioPlex 2200 HSV-1 and HSV-2 IgG kit observed during comparative testing. Refer to Tables 16 - 23 for detailed performance testing summaries.

Table 15: Summary Performance of the BioPlex 2200 HSV-1 and HSV-2 IgG Assay   

<table><tr><td rowspan=2 colspan=1>Population</td><td rowspan=1 colspan=4>BioPlex 2200 HSV-1 lgG</td><td rowspan=1 colspan=4>BioPlex 2200 HSV-2 luG</td></tr><tr><td rowspan=1 colspan=1>Ssi %</td><td rowspan=1 colspan=1>coe10c</td><td rowspan=1 colspan=1>Ss %</td><td rowspan=1 colspan=1>cin20ca</td><td rowspan=1 colspan=1>Ss </td><td rowspan=1 colspan=1>:cod80cia</td><td rowspan=1 colspan=1>Apgds%</td><td rowspan=1 colspan=1>Ccoe1tin</td></tr><tr><td rowspan=1 colspan=1>Sexually ActiveIndividuals With anHSV-1 Test Ordered(N = 289)</td><td rowspan=1 colspan=1>97.6%(202/207)</td><td rowspan=1 colspan=1>94.5*99.0%</td><td rowspan=1 colspan=1>90.1%(73/81)</td><td rowspan=1 colspan=1>81.7-94.99</td><td rowspan=1 colspan=1>NVA</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>Sexually ActiveIndividuals With anHSV-2 Test Ordered(N = 286)</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>90.6%(106/117)</td><td rowspan=1 colspan=1>&#x27;83.9 -94.7%</td><td rowspan=1 colspan=1>98.2%(166/169)</td><td rowspan=1 colspan=1>94.9-99.4%</td></tr><tr><td rowspan=1 colspan=1>Expectant Mothers(N = 399)</td><td rowspan=1 colspan=1>96.3%(287/298)</td><td rowspan=1 colspan=1>93.5 -97.9%</td><td rowspan=1 colspan=1>99.0%(100/101)</td><td rowspan=1 colspan=1>94.6 -99.8%</td><td rowspan=1 colspan=1>96.9%(157/162)</td><td rowspan=1 colspan=1>93.098.7%</td><td rowspan=1 colspan=1>100%(237/237)</td><td rowspan=1 colspan=1>98.4-100%</td></tr><tr><td rowspan=1 colspan=1>CDC Panel(N = 100) </td><td rowspan=1 colspan=1>100%*(50/50)</td><td rowspan=1 colspan=1>92.8 -100% :</td><td rowspan=1 colspan=1>96.0%*-(48/50)-</td><td rowspan=1 colspan=1>86.5 -98:9%</td><td rowspan=1 colspan=1>100%*1t-(50/50)</td><td rowspan=1 colspan=1>92.8 -100%</td><td rowspan=1 colspan=1>100%** (50/50)</td><td rowspan=1 colspan=1>92.8 -100%</td></tr><tr><td rowspan=1 colspan=1>Low Prevalence[16-19 years](N = 200)</td><td rowspan=1 colspan=1>93.3%(97/104)</td><td rowspan=1 colspan=1>86.7 -96.7%</td><td rowspan=1 colspan=1>97.9%(94/96)</td><td rowspan=1 colspan=1>92.7-99.4%</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>97.096(181/185)</td><td rowspan=1 colspan=1>94.6-99.2%</td></tr></table>

![](images/1ad45df78487ad883ac22c352405cce7ff18dfe12951264dc969e6ae62552ca0.jpg)  
\* % Positive Agreement \*\* % Negative Agreement $N / A =$ Not applicable

Performance of the BioPlex 2200 HSV-1 & HSV-2 IgG kit in the intended use populations was tested against a commercially available immunoblot test in a prospective study conducted at a total of 3 U.S. clinical sites. For purposes of sensitivity and specificity calculations, the BioPlex 2200 equivocal results were assigned to the opposite clinical interpretation than that of the corresponding immunoblot result. Likewise, immunoblot equivocal results were assigned to the opposite clinical interpretation than that of the BioPlex 2200 result.

Performance in Sexually Active Individuals

The sensitivity and specificity of the HSV-1 & HSV-2 IgG kit was assessed using remnant serum samples from sexually active individuals where an HsV-1 test was ordered $( N = 2 8 9 )$ and sexually active individuals where an HSv-2 test was ordered $( N = 2 8 6 )$ . Samples were tested at 3 U.S. clinical sites. Combined results from all sites are shown in Tables 16 & 17.

Table 16: Sexually Active Individuals With an HSV-1 Test Ordered: BioPlex 2200 HSV-1 IgG vs.Immunoblot $( N = 2 8 9 )$   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=8>BioPlex 2200 HSv-1 IgG    I.</td></tr><tr><td rowspan=1 colspan=1>agisod</td><td rowspan=1 colspan=1>Ce</td><td rowspan=1 colspan=1>hgeip</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>sniae</td><td rowspan=1 colspan=1>cett</td><td rowspan=1 colspan=1>Seeis</td><td rowspan=1 colspan=1>cec</td></tr><tr><td rowspan=4 colspan=1>AH Cythm i</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>202</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>204</td><td rowspan=4 colspan=1>97.6%(202/207)1• •,</td><td rowspan=4 colspan=1>(94.5 - 99.0%)..i*</td><td rowspan=4 colspan=1>90.1%(73/81)&#x27;       .1.</td><td rowspan=4 colspan=1>(81.7 - 94.9%)</td></tr><tr><td rowspan=1 colspan=1>Equlvocal</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>5</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>73</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>207</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>289</td></tr></table>

Table 17: Sexually Active Individuals With an HSV-2 Test Ordered: BioPlex 2200 HSV-2 IgG vs. Immunoblot $( N = 2 8 6 )$ EY   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=8>BioPlex 2200 HSV-2 IgG</td></tr><tr><td rowspan=1 colspan=1>apsod</td><td rowspan=1 colspan=1>[Cp]</td><td rowspan=1 colspan=1>hgeae</td><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>snsttt*</td><td rowspan=1 colspan=1>c%56 c</td><td rowspan=1 colspan=1>Sids24*&#x27;</td><td rowspan=1 colspan=1>Cae0ct</td></tr><tr><td rowspan=4 colspan=1>MZ-S  Ectmii</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>106</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>117</td><td rowspan=4 colspan=1>90.6%(106/117)</td><td rowspan=4 colspan=1>(83.9 - 94.7%)</td><td rowspan=4 colspan=1>98.2%(166/169)</td><td rowspan=4 colspan=1>(94.9 - 99.4%)</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>D</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>166</td><td rowspan=1 colspan=1>169</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>109</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>176</td><td rowspan=1 colspan=1>286</td></tr></table>

# BIO RAD

Performance in Expectant Mothers The sensitivity and specificily of the HSV-1 & HSV-2 IgG kit was assessed using remnant serum samples from expectant mothers $( N = 3 9 9 )$ . Results are shown in Tables 18 & 19.

Table 18: Expectant Mothers: BioPlex HSV-1 IgG vs. Immunoblot $( N = 3 9 9 )$   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=8>BioPlex 2200 HSV-1.IgG</td></tr><tr><td rowspan=1 colspan=1>Pottttd</td><td rowspan=1 colspan=1>e</td><td rowspan=1 colspan=1>Nefeb</td><td rowspan=1 colspan=1>ea</td><td rowspan=1 colspan=1>{+} sodAa 9</td><td rowspan=1 colspan=1>Copneth</td><td rowspan=1 colspan=1>)eebabW ae d </td><td rowspan=1 colspan=1>Copeteae</td></tr><tr><td rowspan=4 colspan=1>A Cmcytmo</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>287</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>297</td><td rowspan=4 colspan=1>96.3%(287/298)</td><td rowspan=4 colspan=1>(93.5 - 97.996)</td><td rowspan=4 colspan=1>99.0%(100/101)</td><td rowspan=4 colspan=1>(94.6 - 99.896)</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>101</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>288</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>109</td><td rowspan=1 colspan=1>399</td></tr></table>

Table 19: Expectant Mothers: BioPlex HSV-2 IgG vs. Immunoblot $( N = 3 9 9 )$   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=8>BioPlex 2200 HSV-2 IgG</td></tr><tr><td rowspan=1 colspan=1>estid</td><td rowspan=1 colspan=1>Ce</td><td rowspan=1 colspan=1>Neeta</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>(+)engsoduawaby:</td><td rowspan=1 colspan=1>cnnStnenn:5</td><td rowspan=1 colspan=1>(-) anjebaMant:_j</td><td rowspan=1 colspan=1>codceial</td></tr><tr><td rowspan=4 colspan=1>Aha aCpcmounuu</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>157</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>161</td><td rowspan=4 colspan=1>96.9%(157/162)</td><td rowspan=4 colspan=1>(93.0 - 98.7%6)</td><td rowspan=4 colspan=1>100%(237/237)}</td><td rowspan=4 colspan=1>(98.4 - 100%6)</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>237</td><td rowspan=1 colspan=1>237</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>157</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>242</td><td rowspan=1 colspan=1>399</td></tr></table>

# Agreement with CDC Panel

The performance of the BioPlex 2200 HSV-1 & HSV-2 IgG kit was assessed using a masked, well characterized HSV serum panel from the CDC. The panel consists of $2 4 \% H S V _ { 2 } \uparrow$ and HSV-2 dual-positive samples, $50 \%$ HSV-1 positive and $50 \%$ HSV-1 negative samples and $48 \%$ HSV-2 positive and $5 2 \%$ HSV-2 negative samples. The results are presented to convey further information on the performance of the test kit and do not imply endorsement of the assay by the CDC. Results are shown in Tables 20 & 21.

Table 20: BioPlex 2200 HSV-1 IgG vs. CDC HSV Panel $( N = 1 0 0 )$   

<table><tr><td rowspan=2 colspan=2>→</td><td rowspan=1 colspan=8>BioPlex 2200 HSV-1 IgG</td></tr><tr><td rowspan=1 colspan=1>eogsd</td><td rowspan=1 colspan=1>C </td><td rowspan=1 colspan=1>Negena</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>(+) bnodkatd %</td><td rowspan=1 colspan=1>cmi</td><td rowspan=1 colspan=1>(-) nubanWae %</td><td rowspan=1 colspan=1>c10tiee</td></tr><tr><td rowspan=3 colspan=1>CASHDOOResn</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>50</td><td rowspan=3 colspan=1>100%(50/50)</td><td rowspan=3 colspan=1>(92.8 - 100%).</td><td rowspan=3 colspan=1>96.0%(48/50)</td><td rowspan=3 colspan=1>(86.5 - 98.9%)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>50</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>48</td><td rowspan=1 colspan=1>100</td></tr></table>

Table 21: BioPlex 2200 HSV-2 IgG vs. CDC HSV Panel $( N = 1 0 0 )$   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=8>BioPlex 2200 HSV-2 IgG</td></tr><tr><td rowspan=1 colspan=1>. …Pod</td><td rowspan=1 colspan=1>Ce</td><td rowspan=1 colspan=1>angetan</td><td rowspan=1 colspan=1>,.</td><td rowspan=1 colspan=1>  jm %:4(+) autod</td><td rowspan=1 colspan=1>7ri    ct&quot;2  ciee</td><td rowspan=1 colspan=1>:5:(-) aneDanja %</td><td rowspan=1 colspan=1>c20tht</td></tr><tr><td rowspan=3 colspan=1>Z-ASH OO3Rest</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>50</td><td rowspan=3 colspan=1>100%(50/50)</td><td rowspan=3 colspan=1>(92.8 - 100%)</td><td rowspan=3 colspan=1>100%(50/50)(     1</td><td rowspan=3 colspan=1>(92.8 - 100%)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>50</td></tr><tr><td rowspan=1 colspan=1>Total.</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>100</td></tr></table>

![](images/45232408966648a8f14f0b2f981a1b547ed761c8d506ed75f06bc763aacefc36.jpg)

Performance in a Low Prevalence Population

The sensitivity and specificity of the HSV-1 & HSV-2 IgG kit was assessed using remnant serum samples from a low-prevalence population, collected in a non-STD setting, in people age 16-19 $( N = 2 0 0 )$ . Samples were tested at 2 U.S. clinical testing sites. Results are shown in Tables $2 2 \&$ EPY 23.

Table 22: Low-Prevalence Population, Non-STD Setting: BioPlex 2200 HSV-1 IgG vs.Immunoblot $( N = 2 0 0 )$   

<table><tr><td rowspan=2 colspan=2>−</td><td rowspan=1 colspan=8>BioPlex 2200 HSV-1 IgG</td></tr><tr><td rowspan=1 colspan=1>Pothad</td><td rowspan=1 colspan=1>Ceh</td><td rowspan=1 colspan=1>Neee</td><td rowspan=1 colspan=1>er</td><td rowspan=1 colspan=1>(+) !odMab%</td><td rowspan=1 colspan=1>coudineSc</td><td rowspan=1 colspan=1>(-)baaab</td><td rowspan=1 colspan=1>cotneSine</td></tr><tr><td rowspan=4 colspan=1>AaR Cpmcthmounuc</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>97</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>102</td><td rowspan=4 colspan=1>93.3%(97/104)</td><td rowspan=4 colspan=1>(86.7-96.7%)</td><td rowspan=4 colspan=1>97.9%(94/96)</td><td rowspan=4 colspan=1>(92.7 - 99.4%)</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>94</td><td rowspan=1 colspan=1>96</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>99</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>200</td></tr></table>

Table 23: Low-Prevalence Population, Non-STD Setting: . BioPlex 2200 HSV-2 IgG vs. Immunoblot $( N = 2 0 0 )$ EMP   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=8>BioPlex 2200 HSV-2 IgG</td></tr><tr><td rowspan=1 colspan=1>an gisod</td><td rowspan=1 colspan=1>ce</td><td rowspan=1 colspan=1>Negebag</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Asagas %</td><td rowspan=1 colspan=1>ciee2cit</td><td rowspan=1 colspan=1>Speids %</td><td rowspan=1 colspan=1>coie20ciie</td></tr><tr><td rowspan=4 colspan=1>A1- Cpytnounu</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>13</td><td rowspan=4 colspan=1>73.3%(11/15).</td><td rowspan=4 colspan=1>tN/A</td><td rowspan=4 colspan=1>**97.8%(181/185)</td><td rowspan=4 colspan=1>(94.6 - 99.2%)</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>181</td><td rowspan=1 colspan=1>185</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>185</td><td rowspan=1 colspan=1>200</td></tr></table>

popuiation.

# C. Reproducibility Studies

To assess reproducibility of each of the assays in the BioPlex 2200 HSV-1 & HSV-2 IgG kit, a reproducibility panel was prepared at Bio-Rad Laboratories. The reproducibility panel consisted of 8 panel members and the HSV-1 & HSV-2 IgG positive control. The reproducibility panel members were made from diluted patient sera. Reproducibility testing was performed at 2 external evaluation sites and internally at Bio-Rad Laboratories using 3 lots of the HSV-1 & HSV$2 1 9 5$ Reagent Pack, 3 lots of the HSV-1 & HSV-2 IgG Calibrator set and 3 lots of the HSV-1 & HSV-2 IgG Control set (one lot at each site). Each of the reproducibility panel members were tested in duplicate on two runs per day, for 5 days, on 3 lots (2 replicates x 2 runs x 5 days x 3 lots $= 6 0$ replicates per panel member). The data were analyzed for intra-assay and inter-assay reproducibility according to the principles described in the Clinical Laboratory Standards Institute (CLSl) guidance EP15-A2 (Vol. 25, No. 17). The standard deviation (SD) and prevent coefficient of variation $( \% C V )$ were calculated. Results are shown in Tables 24 & 25.

Table 24: Reproducibility: BioPlex 2200 HSV-1 IgG Serum   

<table><tr><td rowspan=3 colspan=1>HSV-1 IgG PanelMembers</td><td rowspan=1 colspan=12>BioPlex 220O HSV-1 lgG:  &quot;    :</td></tr><tr><td rowspan=2 colspan=1>SampleN</td><td rowspan=2 colspan=1>MeanAI</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Site*</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>$D</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>High Positive</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>0.159</td><td rowspan=1 colspan=1>4.4%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.178</td><td rowspan=1 colspan=1>4.9%</td><td rowspan=1 colspan=1>0.081</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>0.252</td><td rowspan=1 colspan=1>6.9%</td></tr><tr><td rowspan=1 colspan=1>High Positive</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>0.132</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>0.095</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>0.125</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>0.413</td><td rowspan=1 colspan=1>10.9%</td><td rowspan=1 colspan=1>0.461</td><td rowspan=1 colspan=1>12.24</td></tr><tr><td rowspan=1 colspan=1>Low Pasitive</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.090</td><td rowspan=1 colspan=1>6.2%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.073</td><td rowspan=1 colspan=1>5.0%</td><td rowspan=1 colspan=1>0.167</td><td rowspan=1 colspan=1>11.49</td><td rowspan=1 colspan=1>0.203</td><td rowspan=1 colspan=1>13.9%</td></tr><tr><td rowspan=1 colspan=1>Low Positive</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.058</td><td rowspan=1 colspan=1>4.5%</td><td rowspan=1 colspan=1>0.034</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>0.058</td><td rowspan=1 colspan=1>4.5%</td><td rowspan=1 colspan=1>0.113</td><td rowspan=1 colspan=1>8.9%</td><td rowspan=1 colspan=1>0.144</td><td rowspan=1 colspan=1>11.34</td></tr><tr><td rowspan=1 colspan=1>Near Cutaff</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.050</td><td rowspan=1 colspan=1>5.2%</td><td rowspan=1 colspan=1>0.018</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>0.047</td><td rowspan=1 colspan=1>4.9%</td><td rowspan=1 colspan=1>0.128</td><td rowspan=1 colspan=1>13.4%</td><td rowspan=1 colspan=1>0.146</td><td rowspan=1 colspan=1>15.3%</td></tr><tr><td rowspan=1 colspan=1>Near Cutoff</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.047</td><td rowspan=1 colspan=1>5.1%</td><td rowspan=1 colspan=1>0.052</td><td rowspan=1 colspan=1>5.6%</td><td rowspan=1 colspan=1>0.030</td><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>&#x27;0.099</td><td rowspan=1 colspan=1>10.7%0</td><td rowspan=1 colspan=1>0.124</td><td rowspan=1 colspan=1>18.546</td></tr><tr><td rowspan=1 colspan=1>High Negative</td><td rowspan=1 colspan=1>59**</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.013</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.018</td><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>0.053</td><td rowspan=1 colspan=1>9.5%</td><td rowspan=1 colspan=1>0.058</td><td rowspan=1 colspan=1>10.3%</td></tr><tr><td rowspan=1 colspan=1>High Negative</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.034</td><td rowspan=1 colspan=1>5.9%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.023</td><td rowspan=1 colspan=1>3.9%</td><td rowspan=1 colspan=1>0.024</td><td rowspan=1 colspan=1>4.2%</td><td rowspan=1 colspan=1>0.048</td><td rowspan=1 colspan=1>8.3%</td></tr><tr><td rowspan=1 colspan=1>Positive Control</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>0.127</td><td rowspan=1 colspan=1>4.2%</td><td rowspan=1 colspan=1>0.092</td><td rowspan=1 colspan=1>3.0%1</td><td rowspan=1 colspan=1>0.108</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>0.137</td><td rowspan=1 colspan=1>4.5%</td><td rowspan=1 colspan=1>0.235</td><td rowspan=1 colspan=1>7.79%</td></tr></table>

\*Between site variance includes between lot variance. On epliat s  o boatoy .

Table 25: Reproducibility: BioPlex 2200 HSV-2 IgG Serum   

<table><tr><td rowspan=3 colspan=1>HSV-2 IgG PanelMembers</td><td rowspan=1 colspan=12>.BioPlex 2200 HSV-2.lgG   &#x27;   - .-,..,.&#x27;             .</td></tr><tr><td rowspan=2 colspan=1>SampleN</td><td rowspan=2 colspan=1>MeanAI</td><td rowspan=1 colspan=2>Within-Rum</td><td rowspan=1 colspan=2>Betweenn-Run</td><td rowspan=1 colspan=2>Between -Day</td><td rowspan=1 colspan=2>Between-Site*</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>High Positive</td><td rowspan=1 colspan=1>59**</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>0.149</td><td rowspan=1 colspan=1>5.0%</td><td rowspan=1 colspan=1>0.124</td><td rowspan=1 colspan=1>4.1%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.155</td><td rowspan=1 colspan=1>5.2%</td><td rowspan=1 colspan=1>0.2491</td><td rowspan=1 colspan=1>8.2%</td></tr><tr><td rowspan=1 colspan=1>High Positive</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>0.121</td><td rowspan=1 colspan=1>3.4%</td><td rowspan=1 colspan=1>0.135</td><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>0.093</td><td rowspan=1 colspan=1>2.6%</td><td rowspan=1 colspan=1>0.226</td><td rowspan=1 colspan=1>6,4%</td><td rowspan=1 colspan=1>0.304</td><td rowspan=1 colspan=1>8.6%</td></tr><tr><td rowspan=1 colspan=1>Low Positive</td><td rowspan=1 colspan=1>60.</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0.111</td><td rowspan=1 colspan=1>6.1%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.074</td><td rowspan=1 colspan=1>4.1%</td><td rowspan=1 colspan=1>0.145</td><td rowspan=1 colspan=1>7.9%</td><td rowspan=1 colspan=1>0.197</td><td rowspan=1 colspan=1>10.7%</td></tr><tr><td rowspan=1 colspan=1>Low Positive</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.061</td><td rowspan=1 colspan=1>4.0%</td><td rowspan=1 colspan=1>0.047</td><td rowspan=1 colspan=1>3.1%</td><td rowspan=1 colspan=1>0.059</td><td rowspan=1 colspan=1>3.9%</td><td rowspan=1 colspan=1>0.117</td><td rowspan=1 colspan=1>7.8%</td><td rowspan=1 colspan=1>0.151</td><td rowspan=1 colspan=1>10.1%</td></tr><tr><td rowspan=1 colspan=1>Near Cutoff</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.052</td><td rowspan=1 colspan=1>4.3%</td><td rowspan=1 colspan=1>0.034</td><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=1>0.059</td><td rowspan=1 colspan=1>4.9%</td><td rowspan=1 colspan=1>0.063</td><td rowspan=1 colspan=1>5.3%</td><td rowspan=1 colspan=1>0.106</td><td rowspan=1 colspan=1>8.9%</td></tr><tr><td rowspan=1 colspan=1>Near Cutoff</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.034</td><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=1>0.072</td><td rowspan=1 colspan=1>6.096</td><td rowspan=1 colspan=1>0.040</td><td rowspan=1 colspan=1>.3.4%</td><td rowspan=1 colspan=1>0.069</td><td rowspan=1 colspan=1>5.8%</td><td rowspan=1 colspan=1>0.113</td><td rowspan=1 colspan=1>9.4%</td></tr><tr><td rowspan=1 colspan=1>High Negative</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.039</td><td rowspan=1 colspan=1>5.2%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.037</td><td rowspan=1 colspan=1>5.1%</td><td rowspan=1 colspan=1>0.058</td><td rowspan=1 colspan=1>7.9%</td><td rowspan=1 colspan=1>0.079</td><td rowspan=1 colspan=1>10.79</td></tr><tr><td rowspan=1 colspan=1>High Negative</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.037</td><td rowspan=1 colspan=1>6.3%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.029</td><td rowspan=1 colspan=1>5.0%</td><td rowspan=1 colspan=1>0.027</td><td rowspan=1 colspan=1>4.7%</td><td rowspan=1 colspan=1>0.054</td><td rowspan=1 colspan=1>9.3%</td></tr><tr><td rowspan=1 colspan=1>Positive Control</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>0.097</td><td rowspan=1 colspan=1>3.4%</td><td rowspan=1 colspan=1>0.092</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>0.088</td><td rowspan=1 colspan=1>3.1%</td><td rowspan=1 colspan=1>0.056</td><td rowspan=1 colspan=1>2.0%[</td><td rowspan=1 colspan=1>0.170</td><td rowspan=1 colspan=1>6.0%</td></tr></table>

\*Between site variance includes between lot variance. ne repliate lost due to aboraty erro

# D. Precision Studles

A Precision panel, consisting of 8 panel members was prepared by Bio-Rad Laboratories. For each analyte, 2 of the 8 panel members had high positive levels of the antibodies, 2 had low positive levels of the antibodies, and 2 had antibody levels near the cutoff; additionally there were 2 high negative panel members. Precision testing was performed at Bio-Rad Laboratories on one lot of the HSV-1 & HSV-2 IgG Reagent Pack, one lot of the HSV-1 & HSV-2 IgG Calibrator Set and one lot of the HSV-1 & HSV-2 IgG Control Set. Each of the 8 panel members was tested in duplicate (x2) on 2 runs per day for 20 days (2 times x 2 runs x 20 days $= 8 0$ replicates per panel member). The data were analyzed for intra-assay and inter-assay precision according to the principles described in the Clinical Laboratory Standards Institute guidance EP5-A2, revised November 2004. The standard deviation (SD) and percent coefficient of variation $( \% C V )$ were calculated. Results are shown in Tables 26 & 27.

Table 26: Precision: BiaPlex 2200 HSV-1 IgG Serum   

<table><tr><td rowspan=3 colspan=1>HSV-1 kgGPanel Members</td><td rowspan=1 colspan=10>..BioPlex 2200 HSV-1 IgG</td></tr><tr><td rowspan=2 colspan=1>SampleN</td><td rowspan=2 colspan=1>MeanAI</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Between Run</td><td rowspan=1 colspan=2>Between Day</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>$D</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>High Positive</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>4.4%</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>5.0%</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.21</td><td rowspan=1 colspan=1>6.6%</td></tr><tr><td rowspan=1 colspan=1>High Positive</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>4.3%</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>5.5%</td></tr><tr><td rowspan=1 colspan=1>Low Positive</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>4.7%</td></tr><tr><td rowspan=1 colspan=1>Low Positive</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>4.9%</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>5.5%</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>7.6%</td></tr><tr><td rowspan=1 colspan=1>Near Cutoff ..</td><td rowspan=1 colspan=1>.80</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>3.4%</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>5.2%</td></tr><tr><td rowspan=1 colspan=1>Near Cutoff</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>3.9%</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>5.29%</td></tr><tr><td rowspan=1 colspan=1>High Negative</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>5.8%</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>6.1%</td></tr><tr><td rowspan=1 colspan=1>High Negative</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>4.5%</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>2.6%</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>6.19%</td></tr></table>

Table 27: Precision: BioPlex 2200 HSV-2 IgG Serum   

<table><tr><td rowspan=3 colspan=1>HSV-2 IgGPanel Members.</td><td rowspan=1 colspan=10>BioPlex 2200 HSV-2 IgG</td></tr><tr><td rowspan=2 colspan=1>SampleN</td><td rowspan=2 colspan=1>MeanAI</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Between Run</td><td rowspan=1 colspan=2>Between Day</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>$D</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>$D</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>$D</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>High Positive</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>0.20</td><td rowspan=1 colspan=1>3.6%</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.5%</td><td rowspan=1 colspan=1>0.26</td><td rowspan=1 colspan=1>4.8%</td></tr><tr><td rowspan=1 colspan=1>High Positive</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>0.17</td><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>0.21</td><td rowspan=1 colspan=1>4.8%</td></tr><tr><td rowspan=1 colspan=1>Low Positive</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>5.2%</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>6.1%</td></tr><tr><td rowspan=1 colspan=1>Low Positive</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>3.6%</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>3.6%</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>6.3%</td></tr><tr><td rowspan=1 colspan=1>Near Cutoff</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>4.9%</td></tr><tr><td rowspan=1 colspan=1>Near Cutoff</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>5.2%</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>6.5%</td></tr><tr><td rowspan=1 colspan=1>High Negative</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>5.8%</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>3.4%</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>6.8%</td></tr><tr><td rowspan=1 colspan=1>High Negative</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>4.6%</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>5.4%</td></tr></table>

# E. Cross-Reactivity

A cross-reactivity study was performed to determine if samples from various disease states and other potentially cross-reacting agents interfere with test results when tested with the BioPlex 2200 HSV-1 & HSV-2 IgG kit. Samples known to be positive for one of the twenty potential crossreactants listed in the table below were evaluated with the BioPlex 2200 HSV-1 & HSV-2 IgG assays. All samples were pre-tested by a commercially available HSV-1 and HSV-2 IgG immunoblot assay and only those that tested negative by the immunoblot assay were further tested by the BioPlex 2200 HSV-1 & HSV-2 IgG kit. Table 28 summarizes negative agreement between the BioPlex 2200 HSV-1 & HSV-2 IgG assays and the corresponding commercially available HSV-1 and HSV-2 IgG immunoblot assay within each of the twenty cross-reactant panels. The results demonstrate that the various disease state samples evaluated do not crossreact with the 2 antigens in the BioPlex 2200.HSV-1 & HSV-2.IgG kit. -:

Table 28: Cross-Reactivity   

<table><tr><td rowspan=2 colspan=1>Potential Cross-Reactant</td><td rowspan=1 colspan=2>HSV-1 IgG</td><td rowspan=1 colspan=2>HSV-2 lIgG</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>BioPlex 2200NegativeAcgreement</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>BioPlex 2200NegativeAgreement</td></tr><tr><td rowspan=1 colspan=1>ANA IgG</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>5/5</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td></tr><tr><td rowspan=1 colspan=1>Candida albicans</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>8/8</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>9/9</td></tr><tr><td rowspan=1 colspan=1>CMVIgG</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>8/8</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>8/8</td></tr><tr><td rowspan=1 colspan=1>E. col</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>S/9</td></tr><tr><td rowspan=1 colspan=1>Toxoplssma gondi IgG</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>8/8</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>8/8</td></tr><tr><td rowspan=1 colspan=1>HCV IgG</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>707</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>9/10*</td></tr><tr><td rowspan=1 colspan=1>VZNV IgG</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td></tr><tr><td rowspan=1 colspan=1>Rubella IgG</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>6/6</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>77</td></tr><tr><td rowspan=1 colspan=1>HBs Antibody</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>.88  y</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1> i19&#x27;</td></tr><tr><td rowspan=1 colspan=1>EBV-VCA IgG</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>707</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>777</td></tr><tr><td rowspan=1 colspan=1>Syphilis IgG</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>4/4</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>717</td></tr><tr><td rowspan=1 colspan=1>N. gonorther</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>4/4</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td></tr><tr><td rowspan=1 colspan=1>HPV IG</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10−</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td></tr><tr><td rowspan=1 colspan=1> C. Imachomatis</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>5/5</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>9/9</td></tr><tr><td rowspan=1 colspan=1>HIV</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>5/5</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid Factor</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>. ….77 </td><td rowspan=1 colspan=1>.g</td><td rowspan=1 colspan=1>-128/9</td></tr><tr><td rowspan=1 colspan=1>Bacterial Vaginosis</td><td rowspan=1 colspan=4>Y</td></tr><tr><td rowspan=1 colspan=1>- Bacteroldes sp.</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>4/6*</td></tr><tr><td rowspan=1 colspan=1>- Tnchonomis</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td></tr><tr><td rowspan=1 colspan=1>- Mobluncus sp.</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1/1</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>4/4</td></tr><tr><td rowspan=1 colspan=1>- Gardenella aginalis</td><td rowspan=1 colspan=1>t0</td><td rowspan=1 colspan=1>10/10</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>10/10</td></tr></table>

\* One (1) HCV sample was identified as low positive for HSV-2 by the BioPlex 2200 HSV-2 IgG assay with an Al value of 1.3. Bes pes we nti S ualan  posivwit va0n respectively, by the BioPlex 2200 HSV-2 lgG assay. $N / A = N a t$ available

# MAY - 8 2009

David V. Bhend   
Regulatory Affairs Representative   
Bio-Rad Laboratories   
$6 5 6 5 ~ \mathrm { { 1 8 5 ^ { t h } } }$ Ave. NE   
Redmond, WA 98052

Re: K090409 Trade/Device Name: BioPlex™M 2200 HSV-1 and HSV-2 IgG Kit Regulation Number: 21 CFR 866.3305 Regulation Name: Herpes simplex virus serological reagents Regulatory Class: Class II Product Code: MXJ,MYF Dated: February 17, 2009 Received: February 18, 2009

Dear Mr. Bhend:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

This letter will allow you to begin marketing your device as described in your Section S10(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at 240-276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,   
Sall al   
Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and   
Radiological Health

# Indication for Use

510(k) Number (if known): k090409

Device Name: BioPlex 2200 HSV-1 and HSV-2 IgG kit on the BioPlex 2200 Multi-Analyte Detection System

Indication For Use:

The BioPlexTM 2200 HSV-1 & HSV-2 IgG kit is a multiplex flow immunoassay intended for the qualitative detection and differentiation of IgG antibodies to herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2) in human serum and EDTA or heparinized plasma. The test is indicated for sexually active individuals and expectant mothers as an aid for the presumptive diagnosis of HSV-1 or HSV-2 infection. The predictive value of positive or negative results depends on the population's prevalence and the pretest likelihood of HSV-1 and HSV-2.

The test is not FDA cleared for screening blood or plasma donors. The performance of this assay has not been established for usc in a pediatric population, neonates and immunocompromised patients or for use at point of care facilities.

The BioPlex 2200 HSV-1 & HSV-2 IgG kit is intended for use with thc Bio-Rad BioPlex 2200 System.

Prescription Use X (21 CFR Part 801 Subpart D)

And/Or

Over the Counter Use (21 CFR Part 801 Subpart C)

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

ln Sif

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

510(k) k010409